Author

Kallanthottathil G. Rajeev

Verve Therapeutics (United States)ORCID 0000-0002-0104-0237Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:non-human primate· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Aaron Beach· 1 shared Alexandra C. ChadwickiD· 1 shared Andrew M. BellingeriD· 1 shared Anne Marie MazzolaiD· 1 shared Chaitali Dutta· 1 shared Christopher Cheng· 1 shared Ellen Rohde· 1 shared Huilan Ren· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetics

Aaron Beach

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver ANGPTL3 editing in wild-type and somatic LDLR knockout non-human primates

Lisa N. Kasiewicz, Souvik Biswas, Aaron Beach, Huilan Ren, Chaitali Dutta, Anne Marie Mazzola, Ellen Rohde, Alexandra C. Chadwick, Christopher Cheng, Kiran Musunuru, Sekar Kathiresan, Padma Malyala, Kallanthottathil G. Rajeev, Andrew M. Bellinger

This study develops GalNAc-LNPs for liver gene editing in NHPs, achieving high editing efficiency and ANGPTL3 reduction in both HoFH and wild-type models.

bioRxiv · Nov 8, 2021 · PreprintGenetics